https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-14 / Biol. Blood Marrow Transplant. 2010 Mar;16(3):320-322009-10-14 00:00:002019-02-15 08:50:56Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 Jun;17(3):821-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 Jun;17(3):821-52009-06-01 00:00:002019-02-15 08:50:57[Dendritic cell-based immunotherapy for multiple myeloma — review]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-732009-02-01 00:00:002019-02-15 08:50:59Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-01-01 / Klin Onkol 2009;22(2):67-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-01-01 / Klin Onkol 2009;22(2):67-722009-01-01 00:00:002019-02-15 08:50:58[The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-01 / Bull Cancer 2008 Mar;95(3):320-62008-03-01 00:00:002019-02-15 08:51:24Immunotherapy of hematological malignancies using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-11-01 / Br. J. Haematol. 2007 Nov;139(3):415-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-11-01 / Br. J. Haematol. 2007 Nov;139(3):415-242007-11-01 00:00:002019-02-15 08:51:00Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-10-01 / Curr Drug Targets 2006 Oct;7(10):1371-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-10-01 / Curr Drug Targets 2006 Oct;7(10):1371-42006-10-01 00:00:002019-02-15 08:51:26Current status of immunotherapy in B cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(3):277-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(3):277-892006-01-01 00:00:002019-02-15 08:51:01Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-372006-01-01 00:00:002019-02-15 08:51:02Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Pathology 2005 Dec;37(6):534-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Pathology 2005 Dec;37(6):534-502005-12-01 00:00:002019-02-15 08:51:27Vaccine strategies to treat lymphoproliferative disorders
